Immunotherapies Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapies stocks.

Immunotherapies Stocks Recent News

Date Stock Title
May 10 RCUS Arcus Biosciences Surpasses Analyst Revenue Forecasts in Q1 2024
May 10 ACLX Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
May 10 RCUS Arcus Biosciences First Quarter 2024 Earnings: Beats Expectations
May 10 ACLX Arcellx GAAP EPS of -$0.14, revenue of $39.3M
May 10 ACLX Kite and Arcellx prepare to launch Phase III multiple myeloma trial
May 9 ACLX Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset
May 9 ACLX Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
May 9 ACLX Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9 ACLX Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9 ACLX Arcellx Provides First Quarter 2024 Financial Results
May 9 RCUS Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2024 Earnings Call Transcript
May 9 RCUS Arcus Biosciences Inc (RCUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 9 RCUS Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript
May 8 RCUS Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
May 8 RCUS Arcus Biosciences GAAP EPS of -$0.05 beats by $0.92, revenue of $145M beats by $116.23M
May 8 RCUS Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
May 8 IMCR Immunocore GAAP EPS of -$0.49 misses by $0.13, revenue of $70.5M beats by $1.32M
May 8 IMCR Immunocore Holdings PLC Reports Q1 2024 Earnings: Misses EPS Estimates, Surpasses Revenue Forecasts
May 8 IMCR Immunocore reports first quarter financial results and provides a business update
May 7 RCUS Arcus Biosciences Q1 2024 Earnings Preview
Immunotherapies

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags